메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 9, Issue 4, 1991, Pages 694-704
Interleukin-2 toxicity
Author keywords

[No Author keywords available]
Indexed keywords

CYTOKINE; INTERLEUKIN 2;
EID: 0026065329     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1991.9.4.694     Document Type: Article
Times cited : (420)
References (13)
  • 1
    • 0024460113 scopus 로고
    • Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma
    • Sznol M, Butcher JP, Atkins MB, et al: Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma. Cancer Treat Rev 16:29-38, 1989
    • (1989) Cancer Treat Rev , vol.16 , pp. 29-38
    • Sznol, M.1    Butcher, J.P.2    Atkins, M.B.3
  • 2
    • 0024426529 scopus 로고
    • Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
    • Rosenberg SA, Lotze M, Yang JC, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-484, 1989
    • (1989) Ann Surg , vol.210 , pp. 474-484
    • Rosenberg, S.A.1    Lotze, M.2    Yang, J.C.3
  • 3
    • 0023230069 scopus 로고
    • The IL-2 receptor beta chain (p70): Role in mediating signals for LAK, NK, and proliferative activities
    • Siegel JP, Sharon M, Smith PL, et al: The IL-2 receptor beta chain (p70): Role in mediating signals for LAK, NK, and proliferative activities. Science 238:75-78, 1987
    • (1987) Science , vol.238 , pp. 75-78
    • Siegel, J.P.1    Sharon, M.2    Smith, P.L.3
  • 4
    • 0023115642 scopus 로고
    • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
    • Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
    • (1987) N Engl J Med , vol.316 , pp. 889-897
    • Rosenberg, S.A.1    Lotze, M.T.2    Muul, L.M.3
  • 5
    • 0024514149 scopus 로고
    • Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines
    • Margolin KA, Rayner AA, Hawkins MJ, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 7:486-498, 1989
    • (1989) J Clin Oncol , vol.7 , pp. 486-498
    • Margolin, K.A.1    Rayner, A.A.2    Hawkins, M.J.3
  • 6
    • 0024512021 scopus 로고
    • Cardiorespiratory effects of immunotherapy with interleukin-2
    • Lee RE, Lotze MT, Skibber JM, et al: Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7:7-20, 1989
    • (1989) J Clin Oncol , vol.7 , pp. 7-20
    • Lee, R.E.1    Lotze, M.T.2    Skibber, J.M.3
  • 7
    • 0024498047 scopus 로고
    • Myocardial toxic effects during recombinant interleukin-2 therapy
    • Nora R, Abrams JS, Tait NS, et al: Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst 81:59-63, 1989
    • (1989) J Natl Cancer Inst , vol.81 , pp. 59-63
    • Nora, R.1    Abrams, J.S.2    Tait, N.S.3
  • 8
    • 0024201472 scopus 로고
    • Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells
    • Mier JW, Aronson FR, Numerof RP, et al: Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res 7:459-476, 1988
    • (1988) Pathol Immunopathol Res , vol.7 , pp. 459-476
    • Mier, J.W.1    Aronson, F.R.2    Numerof, R.P.3
  • 9
    • 0023877108 scopus 로고
    • Myocardial injury after interleukin-2 therapy
    • letter
    • Osanto S, Cluitmans FH, Franks CR, et al: Myocardial injury after interleukin-2 therapy. Lancet 2:48-49, 1988 (letter)
    • (1988) Lancet , vol.2 , pp. 48-49
    • Osanto, S.1    Cluitmans, F.H.2    Franks, C.R.3
  • 10
    • 0024373260 scopus 로고
    • Severe myocarditis following high-dose interleukin-2 administration
    • Samlowski WE, Ward JH, Craven CM, et al: Severe myocarditis following high-dose interleukin-2 administration. Arch Pathol Lab Med 113:838-841, 1989
    • (1989) Arch Pathol Lab Med , vol.113 , pp. 838-841
    • Samlowski, W.E.1    Ward, J.H.2    Craven, C.M.3
  • 11
    • 0024203907 scopus 로고
    • The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells
    • Gaynor ER, Vitek L, Sticklin L, et al: The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 109:953-958, 1988
    • (1988) Ann Intern Med , vol.109 , pp. 953-958
    • Gaynor, E.R.1    Vitek, L.2    Sticklin, L.3
  • 12
    • 0023750345 scopus 로고
    • Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock
    • Ognibene FP, Rosenberg SA, Lotze M, et al: Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94:750-754, 1988
    • (1988) Chest , vol.94 , pp. 750-754
    • Ognibene, F.P.1    Rosenberg, S.A.2    Lotze, M.3
  • 13
    • 0343875590 scopus 로고
    • Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness
    • Gulick T, Chung MK, Pieper SJ, et al: Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA. 86:6753-6757, 1986
    • (1986) Proc Natl Acad Sci USA , vol.86 , pp. 6753-6757
    • Gulick, T.1    Chung, M.K.2    Pieper, S.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.